Harvard Health Letter

Niacin trial stopped early: Now what?

A clinical trial of niacin in combination with a statin to lower cholesterol was stopped early because of concerns that the combined medication could be associated with an increased risk of stroke.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In